FR2835186B1 - Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases - Google Patents

Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases

Info

Publication number
FR2835186B1
FR2835186B1 FR0200951A FR0200951A FR2835186B1 FR 2835186 B1 FR2835186 B1 FR 2835186B1 FR 0200951 A FR0200951 A FR 0200951A FR 0200951 A FR0200951 A FR 0200951A FR 2835186 B1 FR2835186 B1 FR 2835186B1
Authority
FR
France
Prior art keywords
beta
heterocyclic compounds
novel heterocyclic
compounds active
lactamases inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0200951A
Other languages
English (en)
French (fr)
Other versions
FR2835186A1 (fr
Inventor
Jozsef Aszodi
Maxime Lampilas
Claude Fromentin
David Alan Rowlands
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ireland Pharmaceuticals
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27619669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2835186(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Priority to FR0200951A priority Critical patent/FR2835186B1/fr
Priority to JO2002138A priority patent/JO2646B1/en
Priority to TW092101133A priority patent/TWI293071B/zh
Priority to CNB2007100015952A priority patent/CN100563653C/zh
Priority to BR122015020406A priority patent/BR122015020406B8/pt
Priority to MYPI20030260A priority patent/MY140638A/en
Priority to AT03709903T priority patent/ATE484281T1/de
Priority to UA20040807144A priority patent/UA80271C2/uk
Priority to EP03709903A priority patent/EP1480644B1/fr
Priority to DK10177533.6T priority patent/DK2279737T3/da
Priority to HK05109272.5A priority patent/HK1077205B/xx
Priority to UY27626A priority patent/UY27626A1/es
Priority to DE60334527T priority patent/DE60334527D1/de
Priority to PT101775336T priority patent/PT2279737E/pt
Priority to BRPI0307267A priority patent/BRPI0307267B8/pt
Priority to PL371601A priority patent/PL220725B1/pl
Priority to ARP030100226A priority patent/AR038234A1/es
Priority to OA1200400200A priority patent/OA12761A/fr
Priority to YU65804A priority patent/RS52137B/sr
Priority to SI200332240T priority patent/SI2279737T1/sl
Priority to PCT/FR2003/000243 priority patent/WO2003063864A2/fr
Priority to ES03709903T priority patent/ES2356813T3/es
Priority to CNB038028786A priority patent/CN100482225C/zh
Priority to EA200400981A priority patent/EA007220B1/ru
Priority to PT03709903T priority patent/PT1480644E/pt
Priority to CA2474043A priority patent/CA2474043C/fr
Priority to DK03709903.3T priority patent/DK1480644T3/da
Priority to KR1020047011594A priority patent/KR100979079B1/ko
Priority to EP10177533A priority patent/EP2279737B1/fr
Priority to CNA2008101667591A priority patent/CN101406471A/zh
Priority to ES10177533T priority patent/ES2401855T3/es
Priority to MXPA04006621A priority patent/MXPA04006621A/es
Priority to SI200331935T priority patent/SI1480644T1/sl
Priority to PE2003000080A priority patent/PE20030969A1/es
Priority to JP2003563554A priority patent/JP4472346B2/ja
Priority to HRP20040686AA priority patent/HRP20040686B1/hr
Priority to NZ533936A priority patent/NZ533936A/en
Priority to AU2003214335A priority patent/AU2003214335B2/en
Publication of FR2835186A1 publication Critical patent/FR2835186A1/fr
Priority to MA27777A priority patent/MA26351A1/fr
Priority to CR7387A priority patent/CR7387A/es
Priority to ZA2004/05607A priority patent/ZA200405607B/en
Priority to EC2004005193A priority patent/ECSP045193A/es
Priority to IL163167A priority patent/IL163167A/en
Priority to TNP2004000137A priority patent/TNSN04137A1/fr
Priority to CO04071440A priority patent/CO5601014A2/es
Priority to US10/898,754 priority patent/US7612087B2/en
Priority to NO20043587A priority patent/NO335195B1/no
Application granted granted Critical
Publication of FR2835186B1 publication Critical patent/FR2835186B1/fr
Priority to HK07111190.8A priority patent/HK1105864B/xx
Priority to US12/434,270 priority patent/US20090215747A1/en
Priority to US12/610,562 priority patent/US20100048528A1/en
Priority to CY20101101192T priority patent/CY1111061T1/el
Priority to CL2011000009A priority patent/CL2011000009A1/es
Priority to US13/161,783 priority patent/US20110245254A1/en
Priority to CR20120356A priority patent/CR20120356A/es
Priority to CY20131100090T priority patent/CY1114417T1/el
Priority to ARP150101838A priority patent/AR100790A2/es
Priority to CY2016042C priority patent/CY2016042I2/el
Priority to NL300847C priority patent/NL300847I2/nl
Priority to BE2016C069C priority patent/BE2016C069I2/fr
Priority to FR16C1019C priority patent/FR16C1019I2/fr
Priority to LTPA2016037C priority patent/LTC1480644I2/lt
Priority to HUS1600055C priority patent/HUS1600055I1/hu
Priority to NO2016024C priority patent/NO2016024I1/no
Anticipated expiration legal-status Critical
Priority to NO2025027C priority patent/NO2025027I1/no
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR0200951A 2002-01-28 2002-01-28 Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases Expired - Lifetime FR2835186B1 (fr)

Priority Applications (64)

Application Number Priority Date Filing Date Title
FR0200951A FR2835186B1 (fr) 2002-01-28 2002-01-28 Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
JO2002138A JO2646B1 (en) 2002-01-28 2002-12-29 New differentiated cyclic compounds as beta - lactam inhibitors
TW092101133A TWI293071B (en) 2002-01-28 2003-01-20 New heterocyclic compounds, which are active as inhibitors of beta-lactamases
CNB2007100015952A CN100563653C (zh) 2002-01-28 2003-01-27 具有β-内酰胺酶抑制剂活性的杂环化合物
BR122015020406A BR122015020406B8 (pt) 2002-01-28 2003-01-27 uso de compostos de formula i como inibidores de beta-lactamases e composições farmaceuticas
MYPI20030260A MY140638A (en) 2002-01-28 2003-01-27 New heterocyclic compounds, which are active as inhibitors of beta-lactamases
AT03709903T ATE484281T1 (de) 2002-01-28 2003-01-27 Heterocyclische verbindungen die als beta- lactamasehemmer aktiv sind
UA20040807144A UA80271C2 (uk) 2002-01-28 2003-01-27 Застосування гетероциклічних сполук як інгібіторів бета-лактамази
EP03709903A EP1480644B1 (fr) 2002-01-28 2003-01-27 Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
DK10177533.6T DK2279737T3 (da) 2002-01-28 2003-01-27 Heterocycliske forbindelser, der er aktive som beta-lactamaseinhibitorer
HK05109272.5A HK1077205B (en) 2002-01-28 2003-01-27 Novel heterocyclic compounds which are active as inhibitors of beta+lactamases
UY27626A UY27626A1 (es) 2002-01-28 2003-01-27 Nuevos compuestos heterocíclos, activos como inhibidores de beta-lactamasas
DE60334527T DE60334527D1 (de) 2002-01-28 2003-01-27 Heterocyclische verbindungen die als beta-lactamasehemmer aktiv sind
PT101775336T PT2279737E (pt) 2002-01-28 2003-01-27 Compostos heterocíclicos, activos como inibidores de beta-lactamases
BRPI0307267A BRPI0307267B8 (pt) 2002-01-28 2003-01-27 uso de compostos inibidores de beta-lactamases e composições farmacêuticas para terapia antibacteriana
PL371601A PL220725B1 (pl) 2002-01-28 2003-01-27 Zastosowanie związków heterocyklicznych aktywnych jako inhibitor β-laktamazy do wytwarzania leku do leczenia infekcji bakteryjnych u człowieka lub zwierząt, oraz zawierająca je kompozycja farmaceutyczna
ARP030100226A AR038234A1 (es) 2002-01-28 2003-01-27 Compuestos heterociclicos, activos como inhibidores de beta-lactamasas
OA1200400200A OA12761A (fr) 2002-01-28 2003-01-27 Nouveaux composés héterocycliques, actifs comme inhibiteurs de béta-lactamases.
YU65804A RS52137B (sr) 2002-01-28 2003-01-27 Nova heterociklična jedinjenja aktivna kao inhibitori beta-laktamaze
SI200332240T SI2279737T1 (sl) 2002-01-28 2003-01-27 Heterociklične spojine, učinkovite kot inhibitorji beta-laktamaz
PCT/FR2003/000243 WO2003063864A2 (fr) 2002-01-28 2003-01-27 Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
ES03709903T ES2356813T3 (es) 2002-01-28 2003-01-27 Nuevos compuestos heterocíclicos, activos como inhibidores de beta-lactamasas.
CNB038028786A CN100482225C (zh) 2002-01-28 2003-01-27 具有β-内酰胺酶抑制剂活性的新的杂环化合物
EA200400981A EA007220B1 (ru) 2002-01-28 2003-01-27 Новое применение гетероциклических соединений, активных в качестве ингибиторов бета-лактамаз, и содержащие их фармацевтические композиции
PT03709903T PT1480644E (pt) 2002-01-28 2003-01-27 Compostos heterociclícos, activos como inibidores de beta-lactamases
CA2474043A CA2474043C (fr) 2002-01-28 2003-01-27 Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
DK03709903.3T DK1480644T3 (da) 2002-01-28 2003-01-27 Heterocykliske forbindelser, der er aktive som inhibitorer af beta-lactamaser
KR1020047011594A KR100979079B1 (ko) 2002-01-28 2003-01-27 베타 락타마제의 억제제로서 활성인 헤테로사이클릭 화합물을 함유하는 약제학적 조성물
EP10177533A EP2279737B1 (fr) 2002-01-28 2003-01-27 Composés hétérocycliques, actifs comme inhibiteurs de béta-lactamases
CNA2008101667591A CN101406471A (zh) 2002-01-28 2003-01-27 具有β-内酰胺酶抑制剂活性的新的杂环化合物
ES10177533T ES2401855T3 (es) 2002-01-28 2003-01-27 Compuestos heterocíclicos, activos como inhibidores de beta-lactamasas
MXPA04006621A MXPA04006621A (es) 2002-01-28 2003-01-27 Nuevos compuestos heterociclicos, activos como inhibidores de beta-lactamasas.
SI200331935T SI1480644T1 (sl) 2002-01-28 2003-01-27 Heterociklične spojine, učinkovite kot inhibitorji beta-laktamaz
PE2003000080A PE20030969A1 (es) 2002-01-28 2003-01-27 Compuestos heterociclicos, activos inhibidores de beta-lactamasas
JP2003563554A JP4472346B2 (ja) 2002-01-28 2003-01-27 ベータ−ラクタマーゼの阻害剤として活性である新規な複素環化合物
HRP20040686AA HRP20040686B1 (hr) 2002-01-28 2003-01-27 Novi heterocikliäśki spojevi koji djeluju kao inhibitori beta-laktamaza
NZ533936A NZ533936A (en) 2002-01-28 2003-01-27 Novel heterocyclic compounds, which are active as inhibitors of beta-lactamases
AU2003214335A AU2003214335B2 (en) 2002-01-28 2003-01-27 Heterocyclic compounds which are active as inhibitors of beta lactamases
MA27777A MA26351A1 (fr) 2002-01-28 2004-07-12 Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta+lactamases
CR7387A CR7387A (es) 2002-01-28 2004-07-13 Nuevos compuestos heterociclicos activos como inhibidores de las beta- lactamasas
ZA2004/05607A ZA200405607B (en) 2002-01-28 2004-07-14 Heterocyclic compounds which are active as inhibitors of beta-lactamases
EC2004005193A ECSP045193A (es) 2002-01-28 2004-07-15 "nuevos compuestos heterociclicos, activos como inhibidores de beta-lactamasas"
IL163167A IL163167A (en) 2002-01-28 2004-07-22 Heterocyclic compounds which are active as inhibitors of beta lactamases
TNP2004000137A TNSN04137A1 (fr) 2002-01-28 2004-07-23 Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
CO04071440A CO5601014A2 (es) 2002-01-28 2004-07-26 Nuevos compuestos heterociclicos, activos como inhibidores de beta-lactamasas
US10/898,754 US7612087B2 (en) 2002-01-28 2004-07-26 Heterocyclic compounds as inhibitors of beta-lactamases
NO20043587A NO335195B1 (no) 2002-01-28 2004-08-27 Anvendelse av heterocykliske forbindelser som er aktive som inhibitorer av betalaktamaser samt farmasøytisk blanding derav.
HK07111190.8A HK1105864B (en) 2002-01-28 2007-10-17 Heterocyclic compounds which are active as inhibitors of beta-lactamases
US12/434,270 US20090215747A1 (en) 2002-01-28 2009-05-01 Heterocyclic compounds as inhibitors of beta-lactamases
US12/610,562 US20100048528A1 (en) 2002-01-28 2009-11-02 Heterocyclic compounds as inhibitors of beta-lactamases
CY20101101192T CY1111061T1 (el) 2002-01-28 2010-12-23 Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων
CL2011000009A CL2011000009A1 (es) 2002-01-28 2011-01-05 Composicion farmaceutica que comprende un compuesto derivado de (diaza)- u (oxa-aza)-biciclo-octano en combinacion con un antibiotico de beta-lactamina; y el uso de la composicion para inhibir la produccion de beta-lactamasa en una terapia antibacteriana. (divisional de la solicitud 134-2003)
US13/161,783 US20110245254A1 (en) 2002-01-28 2011-06-16 Heterocyclic compounds as inhibitors of beta-lactamases
CR20120356A CR20120356A (es) 2002-01-28 2012-06-28 Nuevos compuestos heterocíclicos activos como inhibidores de beta-lactamasas
CY20131100090T CY1114417T1 (el) 2002-01-28 2013-01-31 Ετεροκυκλικες ενωσεις, δραστικες ως αναστολεις των βητα-λακταμασων
ARP150101838A AR100790A2 (es) 2002-01-28 2015-06-10 COMPUESTOS HETEROCÍCLICOS, ACTIVOS COMO INHIBIDORES DE b-LACTAMAS
CY2016042C CY2016042I2 (el) 2002-01-28 2016-12-06 Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων
NL300847C NL300847I2 (enExample) 2002-01-28 2016-12-08
BE2016C069C BE2016C069I2 (enExample) 2002-01-28 2016-12-12
FR16C1019C FR16C1019I2 (fr) 2002-01-28 2016-12-13 Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
LTPA2016037C LTC1480644I2 (lt) 2002-01-28 2016-12-13 Nauji heterocikliniai junginiai, veiksmingi kaip beta-laktamazės slopikliai
HUS1600055C HUS1600055I1 (hu) 2002-01-28 2016-12-13 Béta-laktamáz-inhibitor aktivitással rendelkezõ új heterociklusos vegyületek
NO2016024C NO2016024I1 (no) 2002-01-28 2016-12-15 Farmasøytisk blanding eller assosisjon som inneholder som aktive ingredienser: (1) ceftazidim eller et salt derav, og (2) avibaktam eller et farmasøytisk akseptabelt salt derav
NO2025027C NO2025027I1 (no) 2002-01-28 2025-06-13 Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0200951A FR2835186B1 (fr) 2002-01-28 2002-01-28 Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases

Publications (2)

Publication Number Publication Date
FR2835186A1 FR2835186A1 (fr) 2003-08-01
FR2835186B1 true FR2835186B1 (fr) 2006-10-20

Family

ID=27619669

Family Applications (2)

Application Number Title Priority Date Filing Date
FR0200951A Expired - Lifetime FR2835186B1 (fr) 2002-01-28 2002-01-28 Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR16C1019C Active FR16C1019I2 (fr) 2002-01-28 2016-12-13 Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR16C1019C Active FR16C1019I2 (fr) 2002-01-28 2016-12-13 Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases

Country Status (44)

Country Link
US (4) US7612087B2 (enExample)
EP (2) EP2279737B1 (enExample)
JP (1) JP4472346B2 (enExample)
KR (1) KR100979079B1 (enExample)
CN (3) CN100482225C (enExample)
AR (2) AR038234A1 (enExample)
AT (1) ATE484281T1 (enExample)
AU (1) AU2003214335B2 (enExample)
BE (1) BE2016C069I2 (enExample)
BR (1) BRPI0307267B8 (enExample)
CA (1) CA2474043C (enExample)
CL (1) CL2011000009A1 (enExample)
CO (1) CO5601014A2 (enExample)
CR (2) CR7387A (enExample)
CY (3) CY1111061T1 (enExample)
DE (1) DE60334527D1 (enExample)
DK (2) DK2279737T3 (enExample)
EA (1) EA007220B1 (enExample)
EC (1) ECSP045193A (enExample)
ES (2) ES2356813T3 (enExample)
FR (2) FR2835186B1 (enExample)
HR (1) HRP20040686B1 (enExample)
HU (1) HUS1600055I1 (enExample)
IL (1) IL163167A (enExample)
JO (1) JO2646B1 (enExample)
LT (1) LTC1480644I2 (enExample)
MA (1) MA26351A1 (enExample)
MX (1) MXPA04006621A (enExample)
MY (1) MY140638A (enExample)
NL (1) NL300847I2 (enExample)
NO (3) NO335195B1 (enExample)
NZ (1) NZ533936A (enExample)
OA (1) OA12761A (enExample)
PE (1) PE20030969A1 (enExample)
PL (1) PL220725B1 (enExample)
PT (2) PT2279737E (enExample)
RS (1) RS52137B (enExample)
SI (2) SI2279737T1 (enExample)
TN (1) TNSN04137A1 (enExample)
TW (1) TWI293071B (enExample)
UA (1) UA80271C2 (enExample)
UY (1) UY27626A1 (enExample)
WO (1) WO2003063864A2 (enExample)
ZA (1) ZA200405607B (enExample)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
US8900637B2 (en) * 2005-12-02 2014-12-02 Lupin Limited Stable taste masked formulations of cephalosporins
DK1965798T3 (da) * 2005-12-07 2011-11-28 Basilea Pharmaceutica Ag Nyttige monobactam-antibiotika
US20090298878A1 (en) * 2006-07-14 2009-12-03 Akira Matsumura Oxime compounds and the use thereof
BRPI0717348A2 (pt) * 2006-10-23 2013-10-15 Irm Llc Composições e processos para inibir captecina proteases
US8563732B2 (en) * 2007-05-31 2013-10-22 Shionogi & Co., Ltd. Oxyimino compounds and the use thereof
FR2921060B1 (fr) * 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
AU2009206119C1 (en) * 2008-01-18 2016-05-26 Merck Sharp & Dohme Llc Beta-lactamase inhibitors
WO2009114921A1 (en) * 2008-03-17 2009-09-24 Dmitrienko Gary I INHIBITORS OF CLASS B AND CLASS D β-LACTAMASES
FR2930553B1 (fr) * 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
JP5501983B2 (ja) * 2008-06-11 2014-05-28 塩野義製薬株式会社 オキシカルバモイル化合物およびその使用
FR2936798B1 (fr) * 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2936951B1 (fr) * 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2937034B1 (fr) * 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
AU2014244235B2 (en) * 2009-10-09 2016-04-21 Pfizer Ireland Pharmaceuticals Polymorphic and pseudopolymorphic forms of a pharmaceutical compound
KR102087313B1 (ko) 2010-08-10 2020-03-11 렘펙스 파머수티클스 인코퍼레이티드 고리형 보론산 에스터 유도체의 제조방법
KR101836554B1 (ko) * 2010-12-22 2018-04-19 메이지 세이카 파루마 가부시키가이샤 광학 활성인 디아자비시클로옥탄 유도체 및 그의 제조법
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
MY165730A (en) * 2011-06-17 2018-04-20 Pfizer Anti Infectives Ab Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
BR112013028813B1 (pt) * 2011-08-27 2020-10-20 Wockhardt Limited derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e composições farmacêuticas que os compreendem
US9102683B2 (en) 2011-08-29 2015-08-11 University Of Utah Research Foundation Heterocyclic compounds
US20130053565A1 (en) * 2011-08-29 2013-02-28 University Of Utah Research Foundation Substituted 3-piperidone compounds
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US8969567B2 (en) * 2011-09-13 2015-03-03 Wockhardt Ltd. Nitrogen containing compounds and their use
ES2640520T3 (es) * 2011-09-13 2017-11-03 Wockhardt Limited Compuestos que contienen nitrógeno y su uso
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
TW201343646A (zh) 2012-03-30 2013-11-01 Cubist Pharm Inc 異□唑β－內醯胺酶抑制劑
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
US8933233B2 (en) 2012-03-30 2015-01-13 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
KR102108590B1 (ko) * 2012-05-30 2020-05-07 메이지 세이카 파루마 가부시키가이샤 신규 β-락타마아제 저해제 및 그의 제조법
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
JP6329147B2 (ja) * 2012-08-25 2018-05-23 ウォックハート リミテッド １，６−ジアザビシクロ［３，２，１］オクタン−７−オン誘導体および細菌感染の処置におけるそれらの使用
UA111925C2 (uk) * 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
AU2014204045B2 (en) 2013-01-04 2018-10-18 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9132140B2 (en) 2013-01-04 2015-09-15 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2014152996A1 (en) 2013-03-14 2014-09-25 Cubist Pharmaceuticals, Inc. Crystalline form of a beta-lactamase inhibitor
MY193210A (en) 2013-09-24 2022-09-26 Meiji Seika Pharma Co Ltd Process for producing diazabicyclooctane derivative
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
ES2842225T3 (es) 2013-10-08 2021-07-13 Meiji Seika Pharma Co Ltd Cristales de derivado de diazabiciclooctano y método de producción para cristales de derivado de diazabiciclooctano
WO2015125031A1 (en) * 2014-02-20 2015-08-27 Wockhardt Limited Pharmaceutical combinations comprising antibacterial agents
CN103896936A (zh) * 2014-03-20 2014-07-02 西安交通大学 (5s,6r)氯唑西林青霉噻唑酸盐及其制备方法和应用
ES2985626T3 (es) 2014-05-05 2024-11-06 Melinta Therapeutics Inc Sales y polimorfos de derivados cíclicos de éster de ácido borónico y usos terapéuticos de los mismos
HUE046836T2 (hu) 2014-05-05 2020-03-30 Rempex Pharmaceuticals Inc Boronát sók szintézise és alkalmazásuk
AU2015264418A1 (en) 2014-05-19 2016-11-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN104059083B (zh) * 2014-05-27 2017-01-04 浙江工业大学 一种手性二环己内酰胺类化合物的不对称合成方法
EA201692301A1 (ru) 2014-07-01 2017-06-30 Ремпекс Фармасьютикалз, Инк. Производные бороновой кислоты и их терапевтическое применение
PT3221313T (pt) 2014-11-17 2019-04-15 Entasis Therapeutics Ltd Terapia combinada para tratamento de infecções bacterianas resistentes
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
ES2821826T3 (es) 2014-12-05 2021-04-27 Meiji Seika Pharma Co Ltd Método para producir cristales de derivado de diazabiciclooctano y preparación liofilizada estable
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
TWI754613B (zh) * 2015-05-07 2022-02-11 法商木塔比利斯公司 雜環化合物及其用於預防或治療細菌感染之用途
WO2017045510A1 (zh) * 2015-09-16 2017-03-23 山东轩竹医药科技有限公司 β-内酰胺酶抑制剂及其用途
HK1254550A1 (zh) 2015-10-02 2019-07-19 乐高化学生物科学股份有限公司 用於抑制β-内酰胺酶的组合物和方法
WO2017156458A1 (en) 2016-03-11 2017-09-14 University Of South Florida Beta-lactamase inhibitors, formulations, and uses thereof
ES2734773T3 (es) 2016-05-27 2019-12-11 Valoralia I Mas D Sl Compuestos de dihidrooxadiazina para tratar infecciones y cáncer
UA124464C2 (uk) 2016-06-30 2021-09-22 Кьюпекс Біофарма, Інк. Похідні боронової кислоти та їх терапевтичні застосування
CN106279163A (zh) * 2016-08-12 2017-01-04 上海龙翔生物医药开发有限公司 一种合成阿维巴坦及其中间体光学异构体的方法
CN107789355B (zh) * 2016-09-07 2022-04-12 湘北威尔曼制药股份有限公司 含有哌拉西林的复方药物组合物及其应用
SMT202200397T1 (it) 2016-09-16 2022-11-18 Entasis Therapeutics Ltd Composti inibitori di beta-lattamasi
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
CN106699756B (zh) * 2016-12-30 2019-10-29 淄博鑫泉医药技术服务有限公司 β内酰胺酶抑制剂阿维巴坦的合成方法
CN110392684A (zh) 2017-02-06 2019-10-29 拜欧蒂姆公司 新型杂环化合物及其在预防或治疗细菌感染中的用途
EA038393B1 (ru) 2017-05-08 2021-08-20 Энтасис Терапеутикс, Инк. Соединения и способы для лечения бактериальных инфекций
WO2018234962A1 (en) 2017-06-20 2018-12-27 Wockhardt Limited Process for o-sulfonation of 1,6-diazabicyclo[3.2.1]octane compounds
WO2019075084A1 (en) 2017-10-11 2019-04-18 Qpex Biopharma, Inc. BORONIC ACID DERIVATIVES AND SYNTHESIS THEREOF
CN109678856B (zh) * 2017-10-18 2020-09-25 新发药业有限公司 一种阿维巴坦中间体的制备方法
TW201925201A (zh) * 2017-11-10 2019-07-01 日商鹽野義製藥股份有限公司 二氮雜二環辛烷衍生物
CN112424209A (zh) 2018-04-20 2021-02-26 Qpex生物制药有限公司 硼酸衍生物及其治疗用途
SI3833665T1 (sl) 2018-08-09 2023-12-29 Antabio Sas Diazabiciklooktanoni kot zaviralci serinskih beta-laktamaz
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN109942579B (zh) * 2019-04-18 2021-06-22 成都千禧莱医药科技有限公司 β-内酰胺酶抑制剂含脲双环化合物及其制备方法和应用
KR20230020419A (ko) 2020-05-05 2023-02-10 큐펙스 바이오파마 인코포레이티드 보론산 유도체 및 합성, 다형체 형태, 그리고 이들의 치료적 용도
EP4146650B1 (en) * 2020-09-01 2026-01-21 Ningxia Academy of Agriculture and Forestry Sciences Beta-lactamase inhibitors and their preparation
WO2022047790A1 (en) * 2020-09-07 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Amidine substituted bicyclic compounds, their preparation, their use as antibacterial agents and beta-lactamase inhibitors
EP4146651A4 (en) 2021-05-07 2024-06-05 Ningxia Academy of Agriculture and Forestry Sciences SULFONYLAMIDINE SUBSTITUTED COMPOUNDS AND THEIR USE AS BETA-LACTAMASE INHIBITORS
WO2023060369A1 (en) * 2021-10-11 2023-04-20 Ningxia Academy Of Agriculture And Forestry Sciences Novel carbimidate substituted bicyclic compounds and their use as beta-lactamase inhibitors
KR20240041506A (ko) 2022-09-23 2024-04-01 주식회사 경보제약 아비박탐 나트륨 염의 안정한 일수화물 형태 및 그의 제조 방법
CN116375706B (zh) * 2023-02-22 2025-02-14 时森海(杭州)医药科技有限公司 阿维巴坦钠关键中间体及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260057A3 (en) 1986-09-02 1989-02-01 The University Of Melbourne 2-oxo-4-carboxy-pyrimidines
ATE117688T1 (de) 1989-06-09 1995-02-15 Upjohn Co Heterozyklische amine mit zns-wirksamkeit.
FR2676230B1 (fr) 1991-05-07 1993-08-27 Centre Nat Rech Scient Nouveaux derives de pyrrolo [1,4]-benzodiazepines, leur procede de preparation et medicaments les contenant.
JPH05339263A (ja) 1992-06-08 1993-12-21 Wakunaga Pharmaceut Co Ltd ジヒドロピリジン誘導体
PT724587E (pt) 1993-09-29 2003-01-31 Univ Maryland Nucleosidos e nucleotidos de anel expandido
KR100197454B1 (ko) * 1993-12-29 1999-06-15 디. 제이. 우드, 스피겔 알렌 제이 디아자비시클릭 뉴로키닌 길항제
EP0702004A2 (de) 1994-09-15 1996-03-20 Ciba-Geigy Ag 2,9-Diamino- und 2-amino-8-carbamoyl-4-hydroxy-alkansäureamid-derivative
GB9505538D0 (en) 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
SE9504618D0 (sv) 1995-12-22 1995-12-22 Astra Ab New Compounds
PL327737A1 (en) * 1996-01-03 1998-12-21 Smithkline Beecham Plc Carbamoyloxylic derivatives of mutiline and their application as bactericides
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
HUP0001741A3 (en) * 1996-08-02 2000-11-28 Smithkline Beecham Plc Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use, process for preparing them, pharmaceuticals contg. them and their use
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
UY25225A1 (es) * 1997-10-29 2000-12-29 Smithkline Beecham Plc Derivados de pleuromutilina utiles como agentes antimicrobianos
EP1070054A1 (en) 1998-04-08 2001-01-24 Takeda Chemical Industries, Ltd. Amine compounds, their production and their use as somatostatin receptor antagonists or agonists
AU4698399A (en) 1998-06-30 2000-01-17 Du Pont Pharmaceuticals Company 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
CO5160344A1 (es) 1998-12-18 2002-05-30 Schering Corp Inhibidores de transferasa de proteina farnesilo
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
CA2386517A1 (en) 1999-10-07 2001-04-12 Takeda Chemical Industries, Ltd. Amine derivatives
WO2001079206A1 (en) 2000-04-18 2001-10-25 Sumitomo Pharmaceuticals Company, Limited Tricyclic quinazolinediones
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
US7179921B2 (en) 2001-02-22 2007-02-20 School Of Pharmacy, University Of London Indoline and tetrahydro-quinolines as prodrugs for tumour treatment
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors

Also Published As

Publication number Publication date
TWI293071B (en) 2008-02-01
FR2835186A1 (fr) 2003-08-01
EP1480644B1 (fr) 2010-10-13
CY2016042I1 (el) 2017-03-15
CY1111061T1 (el) 2015-06-11
NO2025027I1 (no) 2025-06-13
NZ533936A (en) 2007-05-31
SI2279737T1 (sl) 2013-07-31
LTPA2016037I1 (lt) 2017-01-10
WO2003063864A3 (fr) 2004-03-11
NL300847I2 (enExample) 2017-01-03
CO5601014A2 (es) 2006-01-31
JO2646B1 (en) 2012-06-17
AR038234A1 (es) 2005-01-05
NO335195B1 (no) 2014-10-20
UY27626A1 (es) 2003-08-29
US20110245254A1 (en) 2011-10-06
TNSN04137A1 (fr) 2007-03-12
AU2003214335B2 (en) 2007-04-05
ZA200405607B (en) 2005-09-28
US7612087B2 (en) 2009-11-03
BRPI0307267B8 (pt) 2021-05-25
US20100048528A1 (en) 2010-02-25
CA2474043C (fr) 2011-08-02
CY1114417T1 (el) 2016-08-31
CN100482225C (zh) 2009-04-29
CR7387A (es) 2010-10-25
EA200400981A1 (ru) 2005-02-24
NO20043587L (no) 2004-08-27
CN101406471A (zh) 2009-04-15
KR20040081473A (ko) 2004-09-21
CN1994301A (zh) 2007-07-11
DE60334527D1 (de) 2010-11-25
US20050020572A1 (en) 2005-01-27
BR0307267A (pt) 2004-12-07
MY140638A (en) 2010-01-15
SI1480644T1 (sl) 2011-03-31
HK1105864A1 (zh) 2008-02-29
ES2356813T3 (es) 2011-04-13
HRP20040686A2 (en) 2004-12-31
PT1480644E (pt) 2011-01-17
NO2016024I2 (no) 2016-12-15
LTC1480644I2 (lt) 2018-09-10
EP2279737B1 (fr) 2012-10-31
MXPA04006621A (es) 2004-10-04
RS52137B (sr) 2012-08-31
CY2016042I2 (el) 2017-03-15
KR100979079B1 (ko) 2010-08-31
CN100563653C (zh) 2009-12-02
PL371601A1 (pl) 2005-06-27
EA007220B1 (ru) 2006-08-25
DK1480644T3 (da) 2011-01-24
ATE484281T1 (de) 2010-10-15
NO2016024I1 (no) 2016-12-15
AR100790A2 (es) 2016-11-02
BE2016C069I2 (enExample) 2022-05-17
CN1655781A (zh) 2005-08-17
PE20030969A1 (es) 2003-12-12
TW200303305A (en) 2003-09-01
ES2401855T3 (es) 2013-04-25
CL2011000009A1 (es) 2011-03-25
UA80271C2 (uk) 2007-09-10
MA26351A1 (fr) 2004-10-01
HRP20040686B1 (hr) 2013-02-28
CA2474043A1 (fr) 2003-08-07
ECSP045193A (es) 2004-08-27
YU65804A (sh) 2006-08-17
PL220725B1 (pl) 2015-12-31
EP2279737A1 (fr) 2011-02-02
FR16C1019I2 (fr) 2017-12-29
CR20120356A (es) 2012-10-05
EP1480644A2 (fr) 2004-12-01
IL163167A (en) 2010-04-15
HUS1600055I1 (hu) 2017-01-30
JP4472346B2 (ja) 2010-06-02
PT2279737E (pt) 2013-02-01
FR16C1019I1 (fr) 2017-02-03
WO2003063864A2 (fr) 2003-08-07
DK2279737T3 (da) 2013-02-11
JP2005523897A (ja) 2005-08-11
BRPI0307267B1 (pt) 2016-02-10
HK1077205A1 (zh) 2006-02-10
US20090215747A1 (en) 2009-08-27
OA12761A (fr) 2006-07-04

Similar Documents

Publication Publication Date Title
FR2835186B1 (fr) Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
ATE328036T1 (de) Polyolefinzusammensetzung mit hoher zähigkeit
AU2003262023A1 (en) Five-membered heterocyclic compounds
AU2003258045A1 (en) Novel gamma-lactams as beta-secretase inhibitors
DE60313872D1 (de) Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
ITBO20030081A1 (it) Pacchetto di sigarette.
NO20022649D0 (no) Heterocykliske dihydropyrimidiner som kaliumkanal inhibitorer
IL174375A0 (en) Novel heterocyclic compounds as hsp90-inhibitors
DE50309032D1 (de) Fungizide wirkstoffkombinationen
ZA200705075B (en) Novel hydantoin derivatives as metalloproteinase inhibitors
IL183667A0 (en) Novel hydantoin derivatives as metalloproteinase inhibitors
IL183590A0 (en) Hydantoin derivatives useful as metalloproteinase inhibitors
DK1492934T3 (da) Dørenhed
NO20054854D0 (no) Femrings heterocykliske derivater
IS7833A (is) Efnasambönd með sameinaða heteróhringi
FR2844273B1 (fr) Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
DE60324703D1 (de) Barbitursäure derivaten.
AU2003215635A1 (en) Thiazol-2-yl-imine compounds as pde-7 inhibitors
ATE427945T1 (de) Imidazolderivate
IS8042A (is) Benz[1,2,5]thíadíazól efnasambönd
AU2003280578A1 (en) Heterocyclic compounds
AU2003215158A1 (en) 2-(5-(5-carbamimidoyl-1h-heteroaryl))-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors
DK1487802T3 (da) 2,3-diaryl-pyrazolidin-derivater som neurotensin-nedbrydende enzyminhibitorer
AU2003232362A1 (en) 4-pyrazol-phenylalanine derivatives as ace-nep inhibitors
HK1089770A (en) Novel heterocyclic compounds as hsp90-inhibitors

Legal Events

Date Code Title Description
CA Change of address
TP Transmission of property
TP Transmission of property

Owner name: ASTRA ZENECA HOLDING FRANCE, FR

Effective date: 20140610

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

TP Transmission of property

Owner name: PFIZER IRELAND PHARMACEUTICALS, IE

Effective date: 20170830

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20